- Research Article
1
- 10.1016/j.ccl.2025.11.001
Cardiac Rehabilitation and Mental Health.
- May 01, 2026
- Cardiology clinics
- Rui Pedro Albuquerque + 2 more +2
Publications from 2021 to 2026
Showing 10 of 309 papers
Cardiac Rehabilitation and Mental Health.
International Headache Week 2026: March 15-21.
Management of lipid profile and lipid-lowering therapy in the diabetic population of a primary care center according to cardiovascular risk category (SCORE2-Diabetes vs. SCORE).
Tuberosity Displacement in Reverse Shoulder Arthroplasty: Impact in Tuberosity Healing, Resorption and Range of Motion
Lipid-lowering therapy and LDL cholesterol control among high- and very high-risk patients in Portugal: An analysis of the SANTORINI study.
Mitral valve prolapse and cardiac chamber remodelling: a propensity-score-matched CMR study
Abstract Background Mitral valve prolapse (MVP) is the most common valvular abnormality in the population. Emerging evidence suggests that MVP is associated with left ventricular (LV) remodelling and dysfunction regardless of mitral regurgitation (MR) severity mimicking an early stage of dilated cardiomyopathy. However, prior studies have provided scattered results and were limited by small sample size and poor adjustment for confounders. Purpose To assess early cardiac chamber remodelling associated with MVP in absence of significant MR. Methods This multicentre, retrospective case-control study included patients with isolated MVP without significant MR undergoing CMR including late gadolinium enhancement (LGE). Healthy controls (HC) were selected from local databases and included subjects without cardiovascular pathology or significant comorbidities, with normal CMR parameters defined as comprised within normality ranges reported in the literature. Propensity-score-matching (PSM) was performed in a 1:1 nearest neighbour without replacement method (calliper 0.1), based on age, sex, body-surface-area, hypertension, and diabetes. The impact of MVP on cardiac remodelling was quantified using absolute standardized mean differences (SMDs). Results A total of 587 MVP patients and 583 HC were included, with 517 pairs successfully matched after PSM. Compared to HC, MVP patients showed greater left atrial (LA) area (12.2 [10.5 – 14.1] vs. 11.0 [9.5 – 12.4] cm²/m²), left ventricular (LV) end-diastolic-volume (86.3 [72.4–101.4] vs. 76.3 [66.1–86.0] ml/m²), and lower LV ejection-fraction (60.0% [55.2–65.6] vs. 61.0% [58.0–66.0], all p<0.001). MVP patients also showed greater right atrial area, right ventricular end-diastolic-volume, and higher right ventricular ejection-fraction compared to HC (Figure 1). The greatest impact of MVP on remodelling was observed for LV-end-diastolic volume and left atrial size (SMD ~0.55–0.62, respectively), (Figure 2). Among patients with MVP, remodelling was most pronounced in patients with bi-leaflet MVP and LGE. Conclusions In the absence of significant MR, MVP is associated with cardiac chambers’ remodelling with a particular emphasis on LV and LA dilatation.Cardiac chamber parameters in HC vs. MVP Effect size of MVP on cardiac remodeling
Read moreMRI to guide clinical management of rectal cancer: updated consensus recommendations from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR)-PART I primary staging.
To provide up-to-date consensus recommendations on the acquisition, interpretation and reporting of MRI for the primary staging of rectal cancer. A panel of twenty-six abdominal imaging experts from the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) engaged in an online consensus process, led by three non-voting chairs. The process adhered to an adapted version of the RAND-UCLA appropriateness method. A total of 126 items were scored (22 general, 55 on primary staging, 49 on restaging after neoadjuvant treatment) and classified using ≥ 80% as the cut-off to establish consensus. Consensus was reached for 121 items (96%). The current manuscript addresses the resulting general recommendations and those focused on baseline staging. Key updates compared to the previous guideline editions include more detailed recommendations for image acquisition, adoption of the sigmoid take-off as a landmark to discern rectal from sigmoid cancer, updated definition of mesorectal fascia involvement by a distance of ≤ 1 mm, including involvement by irregular nodes and extramural vascular invasion; a transition to a patient-level approach for cN-category assessment with updated criteria for lateral nodes including a ≥ 7 mm size threshold, and recommendations on the limited use of DWI for primary staging. These updated expert consensus recommendations serve as clinical guidelines for the primary staging of rectal cancer using MRI. Recommendations for restaging and response evaluation after neoadjuvant treatment are addressed in a separate publication. Question Since the last ESGAR rectal imaging guideline update, the rectal cancer treatment landscape has further evolved, necessitating updates to the existing guidelines. Findings An online consensus process involving 26 panellists led to 96% consensus across 121 items discussed, including 22 general items and 55 related to primary staging. Clinical relevance Key updates related to primary staging include more detailed recommendations for image acquisition, adoption of the sigmoid take-off, refined criteria for MRF involvement, a new patient-level approach for cN-assessment, and recommendations on the limited use of DWI.
Read moreFGFR Testing in Metastatic Urothelial Carcinoma—Who, When, and How to Test
Metastatic urothelial carcinoma (mUC) is a lethal cancer with limited therapeutic options. Advances in genomic and transcriptomic research have deepened the understanding of mUC biology, leading to the identification of clinically relevant molecular alterations that represent potential actionable targets. This has broadened the treatment landscape of the disease to include novel agents, such as antibody-drug conjugates (e.g., enfortumab vedotin) and targeted therapies, including the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib. Genomic alterations in FGFR3 are well-established oncogenic drivers in bladder cancer and represent predictive biomarkers of response to FGFR-targeted therapies. The phase III THOR trial demonstrated the clinical benefit of erdafitinib in previously treated mUC patients harboring FGFR3 alterations and supported its subsequent approval by the European Medicines Agency. In this context, accurate molecular profiling is essential to guide patient selection for FGFR inhibitor therapy. Equally important is the standardization and timely implementation of FGFR3 testing in clinical practice to optimize treatment planning. This review addresses key considerations in FGFR3 testing in mUC and discusses how it can be routinely incorporated into clinical practice.
Read moreImpact of the rescuer's posture and position, or manikin position on the efficacy and efficiency of chest compressions during cardiopulmonary resuscitation in adults: a systematic review.
Rescuer posture, position, and patient height during chest compressions (CC) influence its efficacy and efficiency. No clear recommendations exist on these aspects. It is essential to systematize the existing knowledge, especially for nurses and healthcare providers involved in resuscitation. To conduct a systematic review about the impact of rescuer posture, position, and manikin/patient height on CC efficacy and efficiency. The study followed PRISMA guidelines and was registered on PROSPERO. Eligibility criteria included peer-reviewed articles or conference papers comparing different rescuer postures, positions, or manikin/patient heights during CC performed with both hands, regarding efficacy or efficiency. Databases consulted: MEDLINE Complete, SPORTDiscus, Cochrane Reviews, and CINAHL Complete. Methodological quality was assessed using the Quality Assessment Tool for Quantitative Studies. Of 6539 articles, only 34 met inclusion criteria. All were observational, used manikins, and were classified as weak in global methodological quality. Compared with standing, several studies suggested the kneeling posture may be associated with more effective and efficient CC. Evidence regarding the optimal patient height, including potential anthropometric-based adjustments, remains limited. Findings across the included studies indicated that variations in hand position appeared to have minimal influence on CC quality. Some studies reported decreased CC quality when rescuers performed CC while walking. The available evidence suggested that performing CC while kneeling on a firm surface may be beneficial when feasible. Future research is needed to further evaluate the impact of bed height, self-selected rescuer position, and their relevance to emergency practice.
Read moreFeasibility of atrial fibrillation burden quantification and its impact on quality-of-life after ablation procedure using continuous monitoring with a smartwatch
BackgroundContinuous atrial fibrillation (AF) burden assessment is clinically relevant post-ablation but often limited by the invasiveness of current monitoring tools. Wearable technology may enable real-world AF burden tracking, but evidence in post-ablation patients is limited.ObjectiveTo assess the feasibility of smartwatch-based AF burden quantification after catheter ablation, including its association with quality-of-life.MethodsThis prospective, single-centre study enrolled a convenience sample of patients undergoing AF ablation. Participants used a smartwatch daily for 12 months within a digital follow-up program (daily smartwatch electrocardiogram (ECG) recommended). AF burden was defined as the percentage of monitored days with AF-detected ECGs. A Bayesian multilevel model examined the association between AF burden and quality-of-life score (AFEQT).ResultsTwenty patients (mean age 52.6 ± 10.3 years; 10% female) were enrolled. Over 12 months, 3604 smartwatch ECGs were collected (mean 180 per participant), with AF detected in 55% of patients. Patients submitted an ECG in 36% of days, and the median AF burden was 1.4% (IQR 4.6%), ranging from 0% to 25%. Quality-of-life improved significantly over time: AFEQT score increased 1.64 points per month (95% Credible Interval: 0.77 to 2.51), with 69% of patients achieving a clinically meaningful improvement. In contrast to AF recurrence as a binary variable, higher AF burden was associated with smaller improvements in AFEQT scores in the Bayesian model (interaction estimate: -0.22; 95% Credible Interval: -0.39 to -0.05). Each 1% increase in AF burden corresponded to an estimated 3.8-point reduction in AFEQT at 12 months.ConclusionSmartwatch-based monitoring is a feasible method for estimating AF burden after ablation. Higher AF burden was associated with smaller improvements in Qol, supporting its relevance as a meaningful outcome metric.Remote Monitoring Workflow12-Month Smartwatch AF burden
Read more